Switch theme
Sign up to access all valuation multiples
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
1989
6.1K+
LTM Revenue $11.2B
LTM EBITDA $1.9B
$125B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vertex Pharmaceuticals has a last 12-month revenue of $11.2B and a last 12-month EBITDA of $1.9B.
In the most recent fiscal year, Vertex Pharmaceuticals achieved revenue of $11.0B and an EBITDA of $486M.
Vertex Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vertex Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9.9B | $11.0B | XXX | XXX | XXX |
| Gross Profit | $7.9B | $8.6B | XXX | XXX | XXX |
| Gross Margin | 80% | 78% | XXX | XXX | XXX |
| EBITDA | $4.6B | $486M | XXX | XXX | XXX |
| EBITDA Margin | 47% | 4% | XXX | XXX | XXX |
| Net Profit | $3.3B | $3.6B | XXX | XXX | XXX |
| Net Margin | 34% | 33% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 17, 2025, Vertex Pharmaceuticals's stock price is $505.
Vertex Pharmaceuticals has current market cap of $130B, and EV of $125B.
See Vertex Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $125B | $130B | XXX | XXX | XXX | XXX | $4.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 17, 2025, Vertex Pharmaceuticals has market cap of $130B and EV of $125B.
Vertex Pharmaceuticals's trades at 11.2x LTM EV/Revenue multiple, and 66.4x LTM EBITDA.
Analysts estimate Vertex Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vertex Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $125B | XXX | XXX | XXX |
| EV/Revenue | 11.4x | XXX | XXX | XXX |
| EV/EBITDA | 257.6x | XXX | XXX | XXX |
| P/E | -242.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -128.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVertex Pharmaceuticals's NTM/LTM revenue growth is 9%
Vertex Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.8M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Vertex Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vertex Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vertex Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -89% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 13% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $1.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 33% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 46% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vertex Pharmaceuticals acquired XXX companies to date.
Last acquisition by Vertex Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Vertex Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vertex Pharmaceuticals founded? | Vertex Pharmaceuticals was founded in 1989. |
| Where is Vertex Pharmaceuticals headquartered? | Vertex Pharmaceuticals is headquartered in United States of America. |
| How many employees does Vertex Pharmaceuticals have? | As of today, Vertex Pharmaceuticals has 6.1K+ employees. |
| Who is the CEO of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's CEO is Dr. Reshma Kewalramani, M.D.. |
| Is Vertex Pharmaceuticals publicy listed? | Yes, Vertex Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Vertex Pharmaceuticals? | Vertex Pharmaceuticals trades under VRTX ticker. |
| When did Vertex Pharmaceuticals go public? | Vertex Pharmaceuticals went public in 1991. |
| Who are competitors of Vertex Pharmaceuticals? | Similar companies to Vertex Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's current market cap is $130B |
| What is the current revenue of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's last 12-month revenue is $11.2B. |
| What is the current EBITDA of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's last 12-month EBITDA is $1.9B. |
| What is the current EV/Revenue multiple of Vertex Pharmaceuticals? | Current revenue multiple of Vertex Pharmaceuticals is 11.2x. |
| What is the current EV/EBITDA multiple of Vertex Pharmaceuticals? | Current EBITDA multiple of Vertex Pharmaceuticals is 66.4x. |
| What is the current revenue growth of Vertex Pharmaceuticals? | Vertex Pharmaceuticals revenue growth between 2023 and 2024 was 12%. |
| Is Vertex Pharmaceuticals profitable? | Yes, Vertex Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
